William Merigan
| Title | Professor |
|---|
| Institution | School of Medicine and Dentistry |
|---|
| Department | Ophthalmology |
|---|
| Address | |
|---|
|
|
|
-
Geng Y, Dubra A, Yin L, Merigan WH, Sharma R, Libby RT, Williams DR. Adaptive optics retinal imaging in the living mouse eye. Biomed Opt Express. 2012 Apr 1; 3(4):715-34.
-
Hunter JJ, Morgan JI, Merigan WH, Sliney DH, Sparrow JR, Williams DR. The susceptibility of the retina to photochemical damage from visible light. Prog Retin Eye Res. 2012 Jan; 31(1):28-42.
-
Yin L, Greenberg K, Hunter JJ, Dalkara D, Kolstad KD, Masella BD, Wolfe R, Visel M, Stone D, Libby RT, Diloreto D, Schaffer D, Flannery J, Williams DR, Merigan WH. Intravitreal injection of AAV2 transduces macaque inner retina. Invest Ophthalmol Vis Sci. 2011 Apr; 52(5):2775-83.
-
Rossi EA, Chung M, Dubra A, Hunter JJ, Merigan WH, Williams DR. Imaging retinal mosaics in the living eye. Eye (Lond). 2011 Mar; 25(3):301-8.
-
Hunter JJ, Masella B, Dubra A, Sharma R, Yin L, Merigan WH, Palczewska G, Palczewski K, Williams DR. Images of photoreceptors in living primate eyes using adaptive optics two-photon ophthalmoscopy. Biomed Opt Express. 2010; 2(1):139-48.
-
Scoles D, Gray DC, Hunter JJ, Wolfe R, Gee BP, Geng Y, Masella BD, Libby RT, Russell S, Williams DR, Merigan WH. In-vivo imaging of retinal nerve fiber layer vasculature: imaging histology comparison. BMC Ophthalmol. 2009; 9:9.
-
Morgan JI, Hunter JJ, Merigan WH, Williams DR. The reduction of retinal autofluorescence caused by light exposure. Invest Ophthalmol Vis Sci. 2009 Dec; 50(12):6015-22.
-
Mitsuyasu RT, Merigan TC, Carr A, Zack JA, Winters MA, Workman C, Bloch M, Lalezari J, Becker S, Thornton L, Akil B, Khanlou H, Finlayson R, McFarlane R, Smith DE, Garsia R, Ma D, Law M, Murray JM, von Kalle C, Ely JA, Patino SM, Knop AE, Wong P, Todd AV, Haughton M, Fuery C, Macpherson JL, Symonds GP, Evans LA, Pond SM, Cooper DA. Phase 2 gene therapy trial of an anti-HIV ribozyme in autologous CD34+ cells. Nat Med. 2009 Mar; 15(3):285-92.
-
Morgan JI, Dubra A, Wolfe R, Merigan WH, Williams DR. In vivo autofluorescence imaging of the human and macaque retinal pigment epithelial cell mosaic. Invest Ophthalmol Vis Sci. 2009 Mar; 50(3):1350-9.
-
Morgan JI, Hunter JJ, Masella B, Wolfe R, Gray DC, Merigan WH, Delori FC, Williams DR. Light-induced retinal changes observed with high-resolution autofluorescence imaging of the retinal pigment epithelium. Invest Ophthalmol Vis Sci. 2008 Aug; 49(8):3715-29.
-
Gray DC, Wolfe R, Gee BP, Scoles D, Geng Y, Masella BD, Dubra A, Luque S, Williams DR, Merigan WH. In vivo imaging of the fine structure of rhodamine-labeled macaque retinal ganglion cells. Invest Ophthalmol Vis Sci. 2008 Jan; 49(1):467-73.
-
Motsinger AA, Ritchie MD, Shafer RW, Robbins GK, Morse GD, Labbe L, Wilkinson GR, Clifford DB, D'Aquila RT, Johnson VA, Pollard RB, Merigan TC, Hirsch MS, Donahue JP, Kim RB, Haas DW. Multilocus genetic interactions and response to efavirenz-containing regimens: an adult AIDS clinical trials group study. Pharmacogenet Genomics. 2006 Nov; 16(11):837-45.
-
Bridging Generations Toward an Understanding of Infectious Disease Pathogenesis, A Festschrift Honoring Thomas Merigan, 27 August 2004, Stanford, California, USA. J Infect Dis. 2006 Sep 15; 194 Suppl 1:S1-64.
-
Gray DC, Merigan W, Wolfing JI, Gee BP, Porter J, Dubra A, Twietmeyer TH, Ahamd K, Tumbar R, Reinholz F, Williams DR. In vivo fluorescence imaging of primate retinal ganglion cells and retinal pigment epithelial cells. Opt Express. 2006 Aug 7; 14(16):7144-58.
-
Gandhi RT, Spritzler J, Chan E, Asmuth DM, Rodriguez B, Merigan TC, Hirsch MS, Shafer RW, Robbins GK, Pollard RB. Effect of baseline- and treatment-related factors on immunologic recovery after initiation of antiretroviral therapy in HIV-1-positive subjects: results from ACTG 384. J Acquir Immune Defic Syndr. 2006 Aug 1; 42(4):426-34.
-
Hayes RD, Merigan WH. Mechanisms of Sensitivity Loss due to Visual Cortex Lesions in Humans and Macaques. Cereb Cortex. 2007 May; 17(5):1117-28.
-
Martin P, Vickrey JF, Proteasa G, Jimenez YL, Wawrzak Z, Winters MA, Merigan TC, Kovari LC. "Wide-open" 1.3 A structure of a multidrug-resistant HIV-1 protease as a drug target. Structure. 2005 Dec; 13(12):1887-95.
-
Haas DW, Smeaton LM, Shafer RW, Robbins GK, Morse GD, Labbe L, Wilkinson GR, Clifford DB, D'Aquila RT, De Gruttola V, Pollard RB, Merigan TC, Hirsch MS, George AL, Donahue JP, Kim RB. Pharmacogenetics of long-term responses to antiretroviral regimens containing Efavirenz and/or Nelfinavir: an Adult Aids Clinical Trials Group Study. J Infect Dis. 2005 Dec 1; 192(11):1931-42.
-
Smith PF, Robbins GK, Shafer RW, Wu H, Yu S, Hirsch MS, Merigan TC, Park JG, Forrest A, Fischl MA, Morse GD. Pharmacokinetics of nelfinavir and efavirenz in antiretroviral-naive, human immunodeficiency virus-infected subjects when administered alone or in combination with nucleoside analog reverse transcriptase inhibitors. Antimicrob Agents Chemother. 2005 Aug; 49(8):3558-61.
-
Winters MA, Merigan TC. Insertions in the human immunodeficiency virus type 1 protease and reverse transcriptase genes: clinical impact and molecular mechanisms. Antimicrob Agents Chemother. 2005 Jul; 49(7):2575-82.
-
Campbell TB, Shulman NS, Johnson SC, Zolopa AR, Young RK, Bushman L, Fletcher CV, Lanier ER, Merigan TC, Kuritzkes DR. Antiviral activity of lamivudine in salvage therapy for multidrug-resistant HIV-1 infection. Clin Infect Dis. 2005 Jul 15; 41(2):236-42.
-
Shulman NS, Delgado J, Bosch RJ, Winters MA, Johnston E, Shafer RW, Katzenstein DA, Merigan TC. Nonnucleoside reverse transcriptase inhibitor phenotypic hypersusceptibility can be demonstrated in different assays. J Acquir Immune Defic Syndr. 2005 May 1; 39(1):78-81.
-
Winters MA, Kagan RM, Heseltine PN, Merigan TC. New two-amino acid insertion near codon 70 of the HIV type 1 protease gene. AIDS Res Hum Retroviruses. 2005 Apr; 21(4):311-3.
-
Winters MA, Kagan RM, Kovari L, Heseltine PN, Merigan TC. Rare one and two amino acid inserts adjacent to codon 103 of the HIV-1 reverse transcriptase (RT) affect susceptibility to non-nucleoside RT inhibitors. Antivir Ther. 2005; 10(2):363-6.
-
Johnston E, Winters MA, Rhee SY, Merigan TC, Schiffer CA, Shafer RW. Association of a novel human immunodeficiency virus type 1 protease substrate cleft mutation, L23I, with protease inhibitor therapy and in vitro drug resistance. Antimicrob Agents Chemother. 2004 Dec; 48(12):4864-8.
-
Al Dhahry SH, Scrimgeour EM, Al Suwaid AR, Al Lawati MR, El Khatim HS, Al Kobaisi MF, Merigan TC. Human immunodeficiency virus type 1 infection in Oman: antiretroviral therapy and frequencies of drug resistance mutations. AIDS Res Hum Retroviruses. 2004 Nov; 20(11):1166-72.
-
Kagan RM, Merigan TC, Winters MA, Heseltine PN. Increasing prevalence of HIV-1 reverse transcriptase mutation K65R correlates with tenofovir utilization. Antivir Ther. 2004 Oct; 9(5):827-8.
-
Merigan WH, Saunders RC. Unilateral deficits in visual perception and learning after unilateral inferotemporal cortex lesions in macaques. Cereb Cortex. 2004 Aug; 14(8):863-71.
-
Eron JJ, Gulick RM, Bartlett JA, Merigan T, Arduino R, Kilby JM, Yangco B, Diers A, Drobnes C, DeMasi R, Greenberg M, Melby T, Raskino C, Rusnak P, Zhang Y, Spence R, Miralles GD. Short-term safety and antiretroviral activity of T-1249, a second-generation fusion inhibitor of HIV. J Infect Dis. 2004 Mar 15; 189(6):1075-83.
-
Logsdon BC, Vickrey JF, Martin P, Proteasa G, Koepke JI, Terlecky SR, Wawrzak Z, Winters MA, Merigan TC, Kovari LC. Crystal structures of a multidrug-resistant human immunodeficiency virus type 1 protease reveal an expanded active-site cavity. J Virol. 2004 Mar; 78(6):3123-32.
-
Kagan R, Winters M, Merigan T, Heseltine P. HIV type 1 genotypic resistance in a clinical database correlates with antiretroviral utilization. AIDS Res Hum Retroviruses. 2004 Jan; 20(1):1-9.
-
Robbins GK, De Gruttola V, Shafer RW, Smeaton LM, Snyder SW, Pettinelli C, Dubé MP, Fischl MA, Pollard RB, Delapenha R, Gedeon L, van der Horst C, Murphy RL, Becker MI, D'Aquila RT, Vella S, Merigan TC, Hirsch MS. Comparison of sequential three-drug regimens as initial therapy for HIV-1 infection. N Engl J Med. 2003 Dec 11; 349(24):2293-303.
-
Shafer RW, Smeaton LM, Robbins GK, De Gruttola V, Snyder SW, D'Aquila RT, Johnson VA, Morse GD, Nokta MA, Martinez AI, Gripshover BM, Kaul P, Haubrich R, Swingle M, McCarty SD, Vella S, Hirsch MS, Merigan TC. Comparison of four-drug regimens and pairs of sequential three-drug regimens as initial therapy for HIV-1 infection. N Engl J Med. 2003 Dec 11; 349(24):2304-15.
-
Jacobson JM, Lederman MM, Spritzler J, Valdez H, Tebas P, Skowron G, Wang R, Jackson JB, Fox L, Landay A, Gilbert MJ, O'Neil D, Bancroft L, Al-Harthi L, Jacobson MA, Merigan TC, Glesby MJ. Granulocyte-macrophage colony-stimulating factor induces modest increases in plasma human immunodeficiency virus (HIV) type 1 RNA levels and CD4+ lymphocyte counts in patients with uncontrolled HIV infection. J Infect Dis. 2003 Dec 15; 188(12):1804-14.
-
Shiramizu B, Theodore D, Bassett R, Coel M, Sherman KE, Glesby MJ, Chow D, Alston B, Colquhoun D, Merigan TC, Reichman RC, Berggren R, Burning WJ, Brobst S. Correlation of single photon emission computed tomography parameters as a noninvasive alternative to liver biopsies in assessing liver involvement in the setting of HIV and hepatitis C virus coinfection: a multicenter trial of the Adult AIDS Clinical Trials Group. J Acquir Immune Defic Syndr. 2003 Jul 1; 33(3):329-35.
-
Vickrey JF, Logsdon BC, Proteasa G, Palmer S, Winters MA, Merigan TC, Kovari LC. HIV-1 protease variants from 100-fold drug resistant clinical isolates: expression, purification, and crystallization. Protein Expr Purif. 2003 Mar; 28(1):165-72.
-
Shimozaki SS, Hayhoe MM, Zelinsky GJ, Weinstein A, Merigan WH, Ballard DH. Effect of parietal lobe lesions on saccade targeting and spatial memory in a naturalistic visual search task. Neuropsychologia. 2003; 41(10):1365-86.
-
Lobato RL, Kim EY, Kagan RM, Merigan TC. Genotypic and phenotypic analysis of a novel 15-base insertion occurring between codons 69 and 70 of HIV type 1 reverse transcriptase. AIDS Res Hum Retroviruses. 2002 Jul 1; 18(10):733-6.
-
Qari SH, Winters M, Vandamme AM, Merigan T, Heneine W. A rapid phenotypic assay for detecting multiple nucleoside analogue reverse transcriptase inhibitor-resistant HIV-1 in plasma. Antivir Ther. 2002 Jun; 7(2):131-9.
-
Baxter JD, Merigan TC, Wentworth DN, Neaton JD, Hoover ML, Hoetelmans RM, Piscitelli SC, Verbiest WH, Mayers DL. Both baseline HIV-1 drug resistance and antiretroviral drug levels are associated with short-term virologic responses to salvage therapy. AIDS. 2002 May 24; 16(8):1131-8.
-
Kim EY, Winters MA, Kagan RM, Merigan TC. Functional correlates of insertion mutations in the protease gene of human immunodeficiency virus type 1 isolates from patients. J Virol. 2001 Nov; 75(22):11227-33.
-
Kundu-Raychaudhuri S, Sevin A, Kilgo P, Nokta M, Pollard RB, Merigan TC. Effect of therapeutic immunization with HIV type 1 recombinant glycoprotein 160 ImmunoAG vaccine in HIV-infected individuals with CD4+ T cell counts of >or=500 and 200-400/mm3 (AIDS Clinical Trials Group Study 246/946). AIDS Res Hum Retroviruses. 2001 Oct 10; 17(15):1371-8.
-
Winters MA, Merigan TC. Variants other than aspartic acid at codon 69 of the human immunodeficiency virus type 1 reverse transcriptase gene affect susceptibility to nuleoside analogs. Antimicrob Agents Chemother. 2001 Aug; 45(8):2276-9.
-
Shafer RW, Hertogs K, Zolopa AR, Warford A, Bloor S, Betts BJ, Merigan TC, Harrigan R, Larder BA. High degree of interlaboratory reproducibility of human immunodeficiency virus type 1 protease and reverse transcriptase sequencing of plasma samples from heavily treated patients. J Clin Microbiol. 2001 Apr; 39(4):1522-9.
-
Kim EY, Vrang L, Oberg B, Merigan TC. Anti-HIV type 1 activity of 3'-fluoro-3'-deoxythymidine for several different multidrug-resistant mutants. AIDS Res Hum Retroviruses. 2001 Mar 20; 17(5):401-7.
-
Winters MA, Coolley KL, Cheng P, Girard YA, Hamdan H, Kovari LC, Merigan TC. Genotypic, phenotypic, and modeling studies of a deletion in the beta3-beta4 region of the human immunodeficiency virus type 1 reverse transcriptase gene that is associated with resistance to nucleoside reverse transcriptase inhibitors. J Virol. 2000 Nov; 74(22):10707-13.
-
Merigan WH. Cortical area V4 is critical for certain texture discriminations, but this effect is not dependent on attention. Vis Neurosci. 2000 Nov-Dec; 17(6):949-58.
-
Schooley RT, Spino C, Kuritzkes D, Walker BD, Valentine FA, Hirsch MS, Cooney E, Friedland G, Kundu S, Merigan TC, McElrath MJ, Collier A, Plaeger S, Mitsuyasu R, Kahn J, Haslett P, Uherova P, deGruttola V, Chiu S, Zhang B, Jones G, Bell D, Ketter N, Twadell T, Chernoff D, Rosandich M. Two double-blinded, randomized, comparative trials of 4 human immunodeficiency virus type 1 (HIV-1) envelope vaccines in HIV-1-infected individuals across a spectrum of disease severity: AIDS Clinical Trials Groups 209 and 214. J Infect Dis. 2000 Nov; 182(5):1357-64.
-
Gray CM, Lawrence J, Ranheim EA, Vierra M, Zupancic M, Winters M, Altman J, Montoya J, Zolopa A, Schapiro J, Haase AT, Merigan TC. Highly active antiretroviral therapy results in HIV type 1 suppression in lymph nodes, increased pools of naive T cells, decreased pools of activated T cells, and diminished frequencies of peripheral activated HIV type 1-specific CD8+ T cells. AIDS Res Hum Retroviruses. 2000 Sep 20; 16(14):1357-69.
-
Huxlin KR, Saunders RC, Marchionini D, Pham HA, Merigan WH. Perceptual deficits after lesions of inferotemporal cortex in macaques. Cereb Cortex. 2000 Jul; 10(7):671-83.
-
Baxter JD, Mayers DL, Wentworth DN, Neaton JD, Hoover ML, Winters MA, Mannheimer SB, Thompson MA, Abrams DI, Brizz BJ, Ioannidis JP, Merigan TC. A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy. CPCRA 046 Study Team for the Terry Beirn Community Programs for Clinical Research on AIDS. AIDS. 2000 Jun 16; 14(9):F83-93.
-
Shapero MH, Kundu SK, Engleman E, Laus R, van Schooten WC, Merigan TC. In vivo persistence of donor cells following adoptive transfer of allogeneic dendritic cells in HIV-infected patients. Cell Transplant. 2000 May-Jun; 9(3):307-17.
-
Winters MA, Baxter JD, Mayers DL, Wentworth DN, Hoover ML, Neaton JD, Merigan TC. Frequency of antiretroviral drug resistance mutations in HIV-1 strains from patients failing triple drug regimens. The Terry Beirn Community Programs for Clinical Research on AIDS. Antivir Ther. 2000 Mar; 5(1):57-63.
-
Kontsevich LL, Tyler CW. Relative contributions of sustained and transient pathways to human stereoprocessing. Vision Res. 2000; 40(23):3245-55.
-
Merigan WH. Sorting the wheat from the chaff in visual perception. Nat Neurosci. 1999 Aug; 2(8):690-1.
-
Huxlin KR, Merigan WH. Deficits in complex visual perception following unilateral temporal lobectomy. J Cogn Neurosci. 1998 May; 10(3):395-407.
-
Merigan WH, Pham HA. V4 lesions in macaques affect both single- and multiple-viewpoint shape discriminations. Vis Neurosci. 1998 Mar-Apr; 15(2):359-67.
-
Merigan W, Freeman A, Meyers SP. Parallel processing streams in human visual cortex. Neuroreport. 1997 Dec 22; 8(18):3985-91.
-
Merigan WH. Basic visual capacities and shape discrimination after lesions of extrastriate area V4 in macaques. Vis Neurosci. 1996 Jan-Feb; 13(1):51-60.
-
Pasternak T, Merigan WH. Motion perception following lesions of the superior temporal sulcus in the monkey. Cereb Cortex. 1994 May-Jun; 4(3):247-59.
-
Page WK, King WM, Merigan W, Maunsell J. Magnocellular or parvocellular lesions in the lateral geniculate nucleus of monkeys cause minor deficits of smooth pursuit eye movements. Vision Res. 1994 Jan; 34(2):223-39.
-
Merigan WH, Nealey TA, Maunsell JH. Visual effects of lesions of cortical area V2 in macaques. J Neurosci. 1993 Jul; 13(7):3180-91.
-
Merigan WH. Colour vision: human V4? Curr Biol. 1993 Apr 1; 3(4):226-9.
-
Merigan WH, Maunsell JH. How parallel are the primate visual pathways? Annu Rev Neurosci. 1993; 16:369-402.
-
Lynch JJ, Silveira LC, Perry VH, Merigan WH. Visual effects of damage to P ganglion cells in macaques. Vis Neurosci. 1992 Jun; 8(6):575-83.
-
Merigan WH, Byrne CE, Maunsell JH. Does primate motion perception depend on the magnocellular pathway? J Neurosci. 1991 Nov; 11(11):3422-9.
-
Merigan WH, Katz LM, Maunsell JH. The effects of parvocellular lateral geniculate lesions on the acuity and contrast sensitivity of macaque monkeys. J Neurosci. 1991 Apr; 11(4):994-1001.
-
Merigan WH, Maunsell JH. Macaque vision after magnocellular lateral geniculate lesions. Vis Neurosci. 1990 Oct; 5(4):347-52.
-
Merigan WH, Katz LM. Spatial resolution across the macaque retina. Vision Res. 1990; 30(7):985-91.
-
Lynch JJ, Eskin TA, Merigan WH. Selective degeneration of the parvocellular-projecting retinal ganglion cells in a New World monkey, Saimiri sciureus. Brain Res. 1989 Oct 16; 499(2):325-32.
-
Lynch JJ, Merigan WH, Eskin TA. Subchronic dosing of macaques with 2,5-hexanedione causes long-lasting motor dysfunction but reversible visual loss. Toxicol Appl Pharmacol. 1989 Mar 15; 98(1):166-80.
-
Merigan WH. Chromatic and achromatic vision of macaques: role of the P pathway. J Neurosci. 1989 Mar; 9(3):776-83.
-
Eskin TA, Merigan WH, Wood RW. Carbon disulfide effects on the visual system. II. Retinogeniculate degeneration. Invest Ophthalmol Vis Sci. 1988 Apr; 29(4):519-27.
-
Merigan WH, Wood RW, Zehl D, Eskin TA. Carbon disulfide effects on the visual system. I. Visual thresholds and ophthalmoscopy. Invest Ophthalmol Vis Sci. 1988 Apr; 29(4):512-8.
-
Merigan WH. Effects of toxicants on visual systems. Neurobehav Toxicol. 1979; 1 Suppl 1:15-22.
-
Ator NA, Merigan WH, McIntire RW. The effects of brief exposures to carbon monoxide on temporally differentiated responding. Environ Res. 1976 Aug; 12(1):75-80.
|
Merigan's Networks
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|
